DexCom (NasdaqGS:DXCM) recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact ...
The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...
Investor's Business Daily on MSN3d
Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't WorriedDexcom stock plunged to a four-month low Monday after the FDA issued a warning letter tied to inspections of two facilities ...
Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM) to be approved by the FDA, Abbott has got the green light for its Lingo device - and ...
We recently published a list of 10 Best Growth Stocks Under $100 to Buy Now. In this article, we are going to take a look at ...
Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...
DexCom DXCM-0.65%decrease; red down pointing triangle received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is ...
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 29.6 ...
DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is working on a written response. The diabetes devices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback